Functional significance of Tie2 signaling in the adult vasculature

Recent Progress in Hormone Research

Volumn 59, Issue , 2004, Pages 51-71

  Peters, Kevin G ^a   Kontos, Christopher D ^b   Lin, P Charles ^c   Wong, Adrianne L ^d   Rao, Prema ^e   Huang, Liwen ^f   Dewhirst, Mark W ^b   Sankar, Sabita ^g  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f Myriad Pharmaceuticals Inc   (United States)

^g CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN GRB2; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BREAST CANCER; ENZYME ACTIVATION; ENZYME REGULATION; MATURATION; MORPHOGENESIS; NONHUMAN; OVARY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN INJURY; VASCULAR ENDOTHELIUM; VASCULARIZATION; ANIMAL; BLOOD VESSEL; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION;

EID: 2342440066     PISSN: 00799963     EISSN: 00799963     Source Type: Journal    
DOI: 10.1210/rp.59.1.51     Document Type: Review

References (88)

1. Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ, Stewart DJ 2003 Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 162:1927-1936
2. Calvert JT, Riney TJ, Kontos CD, Cha EH, Prieto VG, Shea CR, Berg JN, Nevin NC, Simpson SA, Pasyk KA, Speer MC, Peters KG, Marchuk DA 1999 Allelic and locus heterogeneity in inherited venous malformations. Hum Mol Genet 8:1279-1289
3. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh GY 2000 Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 20:2573-2578
4. Conway EM, Collen D, Carmeliet P 2001 Molecular mechanisms of blood vessel growth. Cardiovasc Res 49:507-521
5. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD 1996 Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169
6. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J, Jain V, Bailey K, Karow M, Fandl J, Samuelsson SJ, Ioffe E, Rudge JS, Daly TJ, Radziejewski C, Yancopoulos GD 2003 Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nature Struct Biol 10:38-44
7. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML 1992 tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7:1471-1480
8. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML 1994 Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8:1897-1909
9. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marme D, Augustin HG 2003 Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278:1721-1727
10. Folkman J 2001 Angiogenesis-dependent diseases. Semin Oncol 28:536-542
11. Forde A, Constien R, Grone HJ, Hammerling G, Arnold B 2002 Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. Genesis 33:191-197
12. Fujikawa K, de AS, I, Jain SK, Presman E, Christensen RA, Varticovski L 1999 Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp Cell Res 253:663-672
13. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD 2002 Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3:411-423
14. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA 2000 Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87:603-607
15. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, Campochiaro PA 2000 Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 184:275-284
16. Hangai M, Moon YS, Kitaya N, Chan CK, Wu DY, Peters KG, Ryan SJ, Hinton DR 2001 Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum Gene Ther 12:1311-1321
17. Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K 2002 Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 62:340-348
18. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt B, Detmar M 2002 Activation of the tie2 receptor by angiopoietin-I enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160: 1381-1392
19. Hayes AJ, Huang WQ, Yu J, Maisonpierre PC, Liu A, Kern FG, Lippman ME, McLeskey SW, Li LY 2000 Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 83:1154-1160
20. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ 1999 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998
21. Huang L, Turck CW, Rao P, Peters KG 1995 GRB2 and SH-PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Oncogene 11:2097-2103
22. Iwama A, Hamaguchi I, Hashiyama M, Murayama Y, Yasunaga K, Suda T 1993 Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem Biophys Res Commun 195:301-309
23. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, Dumont DJ 1999 Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274:30896-30905
24. Jones N, Iljin K, Dumont DJ, Alitalo K 2001a Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nature Rev Mol Cell Biol 2:257-267
25. Jones N, Voskas D, Master Z, Sarao R, Jones J, Dumont DJ 2001b Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function. EMBO Rep 2:438-445
26. Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ 2003 A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol 23:2658-2668
27. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY 2000a Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19:4549-4552
28. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY 2000b Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86:24-29
29. Kim I, Kim HG, Moon SO, Chae SW, So JN, Koh KN, Ahn BC, Koh GY 2000c Angiopoietin-I induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 86:952-959
30. Kim I, Moon SO, Park SK, Chae SW, Koh GY 2001 Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89:477-479
31. Kim I, Ryu YS, Kwak HJ, Ahn SY, Oh JL, Yancopoulos GD, Gale NW, Koh GY 2002 EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J 16:1126-1128
32. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M 2001 Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 230:230-242
33. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y 2001 Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61:6248-6254
34. Kontos CD, Stauffer TP, Yang WP, York JD, Huang L, Blanar MA, Meyer T, Peters KG 1998 Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 18:4131-4140
35. Kontos CD, Cha EH, York JD, Peters KG 2002 The endothelial receptor tyrosine kinase Tiel activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol 22:1704-1713
36. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K 1997 Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100:2072-2078
37. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG 1998a Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 95:8829-8834
38. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG 1998b Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49-58
39. Loughna S, Sato TN 2001 Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 20:319-325
40. Lyons MS, Bell B, Stainier D, Peters KG 1998 Isolation of the zebrafish homologues for the tie-1 and tie-2 endothelium-specific receptor tyrosine kinases. Dev Dyn 212:133-140
41. Maisonpierre PC, Goldfarb M, Yancopoulos GD, Gao G 1993 Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene 8:1631-1637
42. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD 1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60
43. Marron MB, Hughes DP, Edge MD, Forder CL, Brindle NP 2000 Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2. J Biol Chem 275:39741-39746
44. Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM, Stainier DY, Sato TN 2000 Universal GFP reporter for the study of vascular development. Genesis 28:75-81
45. Niu XL, Peters KG, Kontos CD 2002 Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J Biol Chem 277:31768-31773
46. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB 2003 Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107:1308-1314
47. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, Sessa WC 2000 Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275:9102-9105
48. Pawson T 2002 Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38(suppl 5):S3-S10
49. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E 1998 Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 77:51-56
50. Pluskey S, Wandless TJ, Walsh CT, Shoelson SE 1995 Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J Biol Chem 270:2897-2900
51. Procopio WN, Pelavin PI, Lee WM, Yeilding NM 1999 Angiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J Biol Chem 274:30196-30201
52. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J 1995 The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14:5884-5891
53. Puri MC, Partanen J, Rossant J, Bernstein A 1999 Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development 126:4569-4580
54. Runting AS, Stacker SA, Wilks AF 1993 tie2, a putative protein tyrosine kinase from a new class of cell surface receptor. Growth Factors 9:99-105
55. Sato TN, Qin Y, Kozak CA, Audus KL 1993 Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 90:9355-9358
56. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y 1995 Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-74
57. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, Deutsch U, Sato TN 1997 Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 94:3058-3063
58. Schlessinger J 2000 Cell signaling by receptor tyrosine kinases. Cell 103:211-225
59. Schnurch H, Risau W 1993 Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119:957-968
60. Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, Horne EL, Kadwell SH, McKee DD, Moore JT 2000 Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure Fold Des 8:1105-1113
61. Shim WS, Teh M, Mack PO, Ge R 2001 Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer 94:6-15
62. Shim WS, Teh M, Bapna A, Kim I, Koh GY, Mack PO, Ge R 2002 Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 279:299-309
63. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM 1998 Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98:2081-2087
64. Siemeister G, Schirner M, Weindel K, Keusch P, Menrad A, Marme D, Martiny-Baron G 1999 Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59:3185-3191
65. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Parikh AA, Fan F, Reinmuth N, Bucana CD, Ellis LM 2002 Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer 87:1182-1187
66. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM 2003 Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63:3370-3377
67. Stratmann A, Risau W, Plate KH 1998 Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466
68. Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH 2001 Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Intl J Cancer 91:273-282
69. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD 1996 Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180
70. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD 1998 Increased vascularization in mice overexpressing angiopoietin-1. Science 282:468-471
71. Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, Honda Y 2003 Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 44:393-402
72. Takahashi T, Takahashi K, St John PL, Fleming PA, Tomemori T, Watanabe T, Abrahamson DR, Drake CJ, Shirasawa T, Daniel TO 2003 A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol 23:1817-1831
73. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR 1999 Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341-345
74. Tanaka S, Sugimachi K, Yamashita YY, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K 2002 Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 35:861-867
75. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ 2001 Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49:659-670
76. Theis M, de Wit C, Schlaeger TM, Eckardt D, Kruger O, Doring B, Risau W, Deutsch U, Pohl U, Willecke K 2001 Endothelium-specific replacement of the connexin43 coding region by a lacZ reporter gene. Genesis 29:1-13
77. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM 1999 Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-2514
78. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, Huang T, Papadopoulos N, Maisonpierre PC, Davis S, Yancopoulos GD 1999 Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96:1904-1909
79. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K 1999 VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381-1390
80. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR 2003 The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111:1373-1380
81. Vikkula M, Boon LM, Carraway KL III, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR 1996 Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87:1181-1190
82. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM 1998 Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273:18514-18521
83. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG 1997 Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81:567-574
84. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J 2000 Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
85. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M 1999 In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159:391-400
86. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ 2003 Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 92:984-991
87. Zhu WH, MacIntyre A, Nicosia RF 2002 Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. Am J Pathol 161: 823-830
88. Ziegler SF, Bird TA, Schneringer JA, Schooley KA, Baum PR 1993 Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene 8:663-670